DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable ...

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation ...

A draft Letter of Undertaking signed by the Chief Executive Officer or designated signing authority of Amgen Canada Inc ... for all promotional material related to Lumakras (sotorasib) as per section ...

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Amgen's market standing. Stay informed and make well-considered decisions with our ...

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) for the treatment of adult patients ...

**NM signifies a non meaningful value. A dash signifies the data is not available.